— Okta shares surged 12.4% after the access management company topped analysts' second-quarter earnings expectation and issued a strong full-year outlook. The company reported adjusted earnings of 31 cents per share, excluding items, on revenues totaling $556 million.
That came in ahead of the earnings per share of 22 cents and $535 million in revenue expected by analysts polled by Refinitiv.— The discount retail stock slumped 4.8% on disappointing third-quarter guidance. For the current period, Five Below said it expects revenues to range between $715 million and $730 million, versus the $738 million expected by analysts polled by StreetAccount. Earnings per share estimates also came in below expectations.
เราได้สรุปข่าวนี้มาให้อ่านอย่างรวดเร็ว หากสนใจข่าว สามารถอ่านฉบับเต็มได้ที่นี่ อ่านเพิ่มเติม:
ประเทศไทย ข่าวล่าสุด, ประเทศไทย หัวข้อข่าว
Similar News:คุณยังสามารถอ่านข่าวที่คล้ายกันนี้ซึ่งเรารวบรวมจากแหล่งข่าวอื่น ๆ ได้
Stocks making the biggest moves after hours: Salesforce, Okta, CrowdStrike, Five Below and moreThese are the stocks posting the largest moves in extended trading.
แหล่ง: NBCNewYork - 🏆 270. / 63 อ่านเพิ่มเติม »
These Stocks Are Moving the Most Today: Salesforce, Okta, UBS, CrowdStrike, Chewy, and MoreSalesforce issues an outlook for the third quarter and fiscal year better than analysts' forecasts, Okta raises its fiscal-year outlook, and UBS reports a...
แหล่ง: MarketWatch - 🏆 3. / 97 อ่านเพิ่มเติม »
These Stocks Are Moving the Most Today: Salesforce, Okta, UBS, Chewy, Palantir, CrowdStrike, and MoreSalesforce issues an outlook for the third quarter and fiscal year better than analysts' forecasts, Okta raises its fiscal-year outlook, and UBS reports a...
แหล่ง: MarketWatch - 🏆 3. / 97 อ่านเพิ่มเติม »
Stocks making the biggest premarket moves: Dollar General, Salesforce, Palantir and moreThese are the stocks posting the largest moves in the premarket.
แหล่ง: NBCPhiladelphia - 🏆 569. / 51 อ่านเพิ่มเติม »
Tilray and Curaleaf Stocks Surge as DEA Considers Reclassifying MarijuanaThe Drug Enforcement Agency said it is considering reclassifying weed as a Schedule 3 drug, rather than as a Schedule 1 substance.
แหล่ง: MarketWatch - 🏆 3. / 97 อ่านเพิ่มเติม »